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Sudden Death During Follow-up After New-onset
Ventricular Tachycardia’s in Vascular Surgery Patients
Tamara Winkel1, Olaf Schouten2, Michiel T. Voute1,
Sanne E. Hoeks1, Mirko de Melis3, Hence J. Verhagen1,
Don Poldermans1. 1Erasmus Medical Center, Rotterdam,
Netherlands; 2Reinier de Graaf Hospital, Delft, Nether-
lands; 3Medtronic BRC BV, Maastricht, Netherlands
Objectives: Vascular surgery patients are at increased
risk for late sudden cardiac death. Identification of patients
at risk during surgery offers the opportunity for focused
therapy.
Methods: We monitored 483 vascular surgery pa-
tients, without a history of cardiac arrhythmias, to identify
perioperative new-onset ventricular tachyarrhythmia’s
(VT) using a continuous electrocardiographic device for 72
hours. Preoperative cardiac risk factors, left ventricular
function, medical therapy, inflammation status, and periop-
erative ischemia were noted in all.
Results: New-onset perioperative VT, defined as sus-
tained VT, was detected in 33 (7%) patients. Patients with
perioperative VT had a significantly worse left ventricular
function (p  0.04), were undertreated with statins (p 
0.02), however their inflammation status did not differ (p
0.18). Patients with VT had a higher incidence of myocar-
dial ischemia, compared to patients without VT (30% vs
18%, p  0.10). VT was preceded by ischemia in 74%.
During a median follow-up of 2.0 years (IQR 1.1-3.1),
cardiac death occurred in 56 patients, in 48 (86%) classified
as sudden death. In patients with VT 27% died; 78% were
due to sudden cardiac death. After adjusting for risk factors,
new-onset perioperative VT was associated with sudden
cardiac death (HR 2.3; 95% CI 1.2-5.7, figure).
Conclusions: Late sudden cardiac death is associated
with perioperative VT. Cardiac high-risk patients with peri-
operative VT might constitute a population that could
benefit from preemptive ICD implantation, on top of op-
timal medical therapy.
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Combined Endovascular and Surgical Treatment of
Severe (TASC D) Aortoiliac Occlusive Disease
Vikram S. Kashyap, Turki Albacker. Vascular Surgery,
Cleveland Clinic, Cleveland, OH
Background: Aortobifemoral bypass grafting has been
the traditional treatment for extensive aorto-iliac occlusive
disease (AIOD). We present a case of recanalization, percuta-
neous transluminal angioplasty and stenting (R/PTAS) of the
iliac vessels combined with femoral endarterectomy in a pa-
tient with severe AIOD. We have performed nearly 100 of
these procedureswith goodmid-term resolutionof symptoms
and durability. Concomitant treatment of femoral disease
often needed. R/PTAS is a suitable, lessinvasive alternative to
aortic reconstruction for treatment of patients with severe
AIOD.
Technical Description: A 63-year-old male business-
man had debilitating claudication at 20-30 m. He had a
complicated recovery from recent cardiac surgery with a
prolonged hospitalization. His other co-morbidities in-
cluded diabetes, emphysema, and100 pack year smoking
history. Preoperative studies revealed absent R-sided
pulses, dampened PVR waveforms and CTA showing ex-
tensive bilateral iliac disease (TASC D). The operative
sequence was angiography, R iliac recanalization, R femoral
endarterectomy and patching, stenting of both iliacs and
then patch closure. The key technical components include
long-segment arterial recanalization, aortic re-entry, and
intervention via the patch prior to completion. The patient
had resolution of symptoms, palpable femoral arteries, and
normalization of PVR waveforms.
Author Disclosures: T. Albacker: Nothing to disclose;
V. S. Kashyap: Nothing to disclose.
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A Regional Quality Improvement Effort to Increase
Preoperative Beta-Blocker Utilization
Brian Nolan1, Jens Eldrup-Jorgensen3, Adam Beck1, An-
drew Stanley2, Philip P. Goodney1, Andres Schanzer4,
Donald Likosky1, Jack L. Cronenwett1. 1Dartmouth-
Hitchcock Medical Center, Lebanon, NH; 2Fletcher Allen
Medical Center, Burlington, VT; 3Maine Medical Center,
Portland, ME; 4University of Massachusetts Medical Cen-
ter, Worcester, MA
Objectives:To determine if a regional quality improve-
ment effort can increase preoperative beta-blocker (BB)
usage and decrease postoperative MI (POMI) rate.
